NO20040686L - Forbindelser som pavirker glukokinase - Google Patents

Forbindelser som pavirker glukokinase

Info

Publication number
NO20040686L
NO20040686L NO20040686A NO20040686A NO20040686L NO 20040686 L NO20040686 L NO 20040686L NO 20040686 A NO20040686 A NO 20040686A NO 20040686 A NO20040686 A NO 20040686A NO 20040686 L NO20040686 L NO 20040686L
Authority
NO
Norway
Prior art keywords
glucokinase
affect
compounds
affect glucokinase
Prior art date
Application number
NO20040686A
Other languages
English (en)
Norwegian (no)
Inventor
Peter William Rodney Caulkett
Rodney Brian Hargreaves
Craig Johnstone
Michael Howard Block
Darren Mckerrecher
Clifford David Jones
Roger James
Scott Boyd
Suzanne Saxon Bowker
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20040686L publication Critical patent/NO20040686L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20040686A 2001-08-17 2004-02-17 Forbindelser som pavirker glukokinase NO20040686L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102764A SE0102764D0 (sv) 2001-08-17 2001-08-17 Compounds
PCT/GB2002/003745 WO2003015774A1 (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase

Publications (1)

Publication Number Publication Date
NO20040686L true NO20040686L (no) 2004-02-17

Family

ID=20285065

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040686A NO20040686L (no) 2001-08-17 2004-02-17 Forbindelser som pavirker glukokinase

Country Status (32)

Country Link
US (3) US7390908B2 (hu)
EP (12) EP1669069B1 (hu)
JP (2) JP3987829B2 (hu)
KR (1) KR100920439B1 (hu)
CN (4) CN100577163C (hu)
AR (1) AR037898A1 (hu)
AT (11) ATE359781T1 (hu)
AU (1) AU2002321462B2 (hu)
BR (1) BR0212008A (hu)
CA (1) CA2457410C (hu)
CO (1) CO5560563A2 (hu)
CY (5) CY1105746T1 (hu)
DE (11) DE60228143D1 (hu)
DK (5) DK1669068T3 (hu)
ES (10) ES2307238T3 (hu)
HK (10) HK1079692A1 (hu)
HU (1) HUP0401213A3 (hu)
IL (2) IL160219A0 (hu)
IS (1) IS7150A (hu)
MX (1) MXPA04001500A (hu)
MY (1) MY146279A (hu)
NO (1) NO20040686L (hu)
NZ (1) NZ531193A (hu)
PL (1) PL368970A1 (hu)
PT (5) PT1529530E (hu)
RU (1) RU2329043C9 (hu)
SE (1) SE0102764D0 (hu)
SI (5) SI1568367T1 (hu)
TW (1) TWI333855B (hu)
UA (1) UA83182C2 (hu)
WO (1) WO2003015774A1 (hu)
ZA (1) ZA200401015B (hu)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003262023A1 (en) 2002-09-10 2004-04-30 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
JP2004123732A (ja) * 2002-09-10 2004-04-22 Takeda Chem Ind Ltd ５員複素環化合物
CN1703408A (zh) 2002-10-03 2005-11-30 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑－2－基)酰胺或磺酰胺
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
ATE517887T1 (de) 2003-02-13 2011-08-15 Msd Kk Neue 2-pyridincarbonsäureamidderivate
CN101712657A (zh) 2003-02-26 2010-05-26 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
EP1635821B1 (en) * 2003-05-02 2009-07-08 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl)amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
JP2006526015A (ja) * 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
CA2528785A1 (en) * 2003-06-20 2005-01-06 Matthias Heinrich Nettekoven 2-amidobenzothiazoles as cb1 receptor inverse agonists
ES2222822B1 (es) * 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos.
JP4667384B2 (ja) 2003-10-07 2011-04-13 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
CA2554686A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
JP2007523142A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ ベンズアミド誘導体、およびグルコキナーゼ活性化物質としてのそれらの使用
JP4700684B2 (ja) 2004-04-02 2011-06-15 ノバルティス アーゲー ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
EP1737870A1 (en) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100739367B1 (ko) * 2004-07-14 2007-07-16 크리스탈지노믹스(주) 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
AU2006250354A1 (en) * 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
GB0510852D0 (en) * 2005-05-27 2005-07-06 Astrazeneca Ab Chemical compounds
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
NZ575513A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
GB0514173D0 (en) * 2005-07-09 2005-08-17 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
ES2487967T3 (es) * 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
WO2007125103A2 (en) * 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
EP2019823B1 (en) * 2006-04-28 2010-11-24 TransTech Pharma, Inc. Benzamide glucokinase activators
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
CN107007581A (zh) 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
WO2008031534A1 (en) 2006-09-11 2008-03-20 Syngenta Participations Ag Insecticidal compounds
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) * 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
UA95815C2 (en) * 2006-10-26 2011-09-12 Астразенека Аб Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
WO2008062739A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
BRPI0720254A2 (pt) * 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
KR20090090390A (ko) * 2006-12-21 2009-08-25 아스트라제네카 아베 Ｇｌｋ 활성제로서 유용한 신규 결정 화합물
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
JP5491871B2 (ja) * 2007-02-28 2014-05-14 アドビナス セラピュティックス プライベート リミテッド グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2155720B1 (en) 2007-06-08 2013-07-17 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
CN101711238A (zh) * 2007-06-11 2010-05-19 百时美施贵宝公司 1,3-二羟基取代的苯基酰胺葡糖激酶激活剂
JP5676258B2 (ja) * 2007-08-03 2015-02-25 ロマーク ラボラトリース，エル．シー． アルキルスルホニル置換チアゾリド化合物
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
TW200922582A (en) * 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
BRPI0818501A2 (pt) 2007-10-08 2015-04-22 Advinus Therapeutics Private Ltd Derivados de acetamida como ativadores de glicoquinase, seu processo e aplicações medicinais
NZ585236A (en) * 2007-10-09 2012-03-30 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
DK2197849T3 (da) * 2007-10-09 2013-03-25 Merck Patent Gmbh N-(pyrazol-3-yl)-benzamidderivater som glucosinaseaktivatorer
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
JP5658138B2 (ja) 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
KR101006311B1 (ko) * 2008-06-27 2011-01-06 김정이 온수를 이용한 황토 온열매트 및 그 제조방법
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009278929B2 (en) 2008-08-04 2012-07-05 Astrazeneca Ab Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
SG172853A1 (en) 2009-01-26 2011-08-29 Nanoink Inc Large area, homogeneous array fabrication including substrate temperature control
US8214916B2 (en) 2009-01-26 2012-07-03 Nanoink, Inc. Large area, homogeneous array fabrication including leveling with use of bright spots
KR20110124214A (ko) 2009-01-26 2011-11-16 나노잉크, 인크. 균일한 기판을 포함하는 넓은 면적의 균일한 어레이 제작
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
JP5918124B2 (ja) 2009-05-12 2016-05-18 ロマーク ラボラトリーズ エル．シー． ハロアルキルヘテロアリールベンズアミド化合物
MX341877B (es) 2009-06-26 2016-09-06 Romark Laboratories L C * Compuestos y métodos para tratar influenza.
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
UA103807C2 (ru) * 2009-07-31 2013-11-25 Кадила Хелткере Лимитед Замещенные бензамидные производные как активаторы глюкокиназы (gk)
WO2011081280A2 (en) * 2009-09-22 2011-07-07 Yuhan Corporation Novel glucokinase activators and processes for the preparation thereof
RU2554349C9 (ru) * 2009-09-25 2016-11-27 Байер Интеллектуэль Проперти Гмбх N-(1,2,5-оксадиазол-3-ил)бензамиды и их применение в качестве гербицидов
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20130281708A1 (en) * 2010-03-18 2013-10-24 Takeda California, Inc. Process for the Production of 2-Amino-5-Fluorothiazole
WO2011135355A1 (en) 2010-04-29 2011-11-03 Astrazeneca Ab 3-{ [5 -(azetidin-1-ylcarbonyl)pyrazin-2 -yl] oxy} -5-{ [(1s) -2 -hydroxy- 1 -methylethyl]oxy} -n- (5 -methylpyrazin-2-) benzamid monohydrate
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012054367A1 (en) * 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
CN103269593A (zh) * 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
CA2870488A1 (en) 2012-04-16 2013-10-24 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
AU2013203600C1 (en) 2012-07-13 2016-11-24 University Of Tennessee Research Foundation A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
CN102942541B (zh) * 2012-12-04 2014-07-23 西北师范大学 一种受体化合物及其合成和在比色检测氟离子中的应用
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
AU2014254392B2 (en) * 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104672218A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途
CN104672219A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018183122A1 (en) * 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN110606831A (zh) * 2018-06-14 2019-12-24 上海度德医药科技有限公司 一种Iclaprim的新中间体及其制备方法和应用
CN109879818A (zh) * 2019-04-04 2019-06-14 安徽丰乐农化有限责任公司 N-(4,6-二甲氧基嘧啶-2-基)-4-甲砜基-2-硝基苯甲酰胺的合成方法
US20230014226A1 (en) * 2019-06-24 2023-01-19 Benevolentai Bio Limited New compounds and methods
DE102021131664A1 (de) * 2020-12-04 2022-06-09 Jiangxi Univate New Material Co., LTD. Verfahren zum Vorbereiten einer N-Cyclopropylmethylanilin-Verbindung

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
FR1526074A (fr) 1967-03-22 1968-05-24 Rech S Ind S O R I Soc D Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation
FR2088019A1 (en) 1970-05-08 1972-01-07 Rabot Ets David Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
GB1352415A (en) 1970-05-03 1974-05-08 Boots Co Ltd Esters of substituted nicotine acids
CS173097B1 (hu) 1972-12-01 1977-02-28
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPS5734314B2 (hu) 1973-12-22 1982-07-22
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
GB1588242A (en) 1977-10-28 1981-04-23 May & Baker Ltd N-(tetrazol-5-yl)-salicylamide derivatives
US4474792A (en) 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
JPS5721320A (en) 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5775962A (en) 1980-10-29 1982-05-12 Shionogi & Co Ltd 2-alkoxybenzamide derivative
FR2493848B2 (fr) 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
JPS61205937A (ja) 1985-03-09 1986-09-12 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
JPS62158252A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンベンズアミド誘導体
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
DE3822449A1 (de) 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
JPH03181465A (ja) 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
JPH04300874A (ja) 1991-03-29 1992-10-23 Tsumura & Co 新規２，４−ジアミノ−１，３，５−トリアジン誘導体
JPH04300832A (ja) 1991-03-29 1992-10-23 Tsumura & Co ２，４−ジアミノ−１，３，５−トリアジン誘導体を有　　　　　　　　　　　効成分とするロイコトリエン拮抗剤
US5466715A (en) 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
JPH0627025A (ja) 1992-07-06 1994-02-04 Toto Ltd 分子認識機能膜及びこれを用いたセンサー
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
AU687440B2 (en) 1993-08-24 1998-02-26 Medivir Ab Compounds and methods for inhibition of HIV and related viruses
CA2169719C (en) 1994-06-21 2002-04-16 Yasuo Shoji Pyrazolo[1,5-a]pyrimidine derivative
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5792109A (en) 1994-09-01 1998-08-11 Leland L. Ladd Irrigation pump and system
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
JPH08143565A (ja) 1994-11-16 1996-06-04 Fujisawa Pharmaceut Co Ltd ベンズアミド化合物
US5510478A (en) 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
CA2208011A1 (en) 1994-12-20 1996-06-27 F. Hoffmann-La Roche Ag Aryl-and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5700796A (en) 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5536718A (en) 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5696112A (en) 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
JPH08301760A (ja) 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
DK0870765T3 (da) 1995-05-18 2004-02-23 Zeria Pharm Co Ltd Aminothiazolderivat, lægemiddel indeholdende samme og mellemprodukt til fremstilling af forbindelsen
JP3168915B2 (ja) 1995-05-25 2001-05-21 田辺製薬株式会社 医薬組成物
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
JP3735741B2 (ja) 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
JP3870298B2 (ja) 1996-06-06 2007-01-17 株式会社大塚製薬工場 アミド誘導体
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) * 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
JPH10212271A (ja) 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
JPH1129480A (ja) 1997-05-12 1999-02-02 Otsuka Pharmaceut Factory Inc 縮環ピリミジン誘導体を含有する医薬組成物
WO1999000359A1 (fr) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Derives de noyau aromatique
EP0995742A4 (en) * 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6114483A (en) 1997-08-27 2000-09-05 E. I. Du Pont De Nemours And Company Polymerization of olefins
AU1052599A (en) 1997-11-12 1999-05-31 Institute Of Medicinal Molecular Design. Inc. Retinoid receptor agonists
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
ES2317688T3 (es) * 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
JP3937367B2 (ja) 1998-02-05 2007-06-27 株式会社大塚製薬工場 一酸化窒素合成酵素阻害剤
JPH11292879A (ja) 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc カルボキサミド誘導体
DE19816780A1 (de) * 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
WO2000039118A1 (en) * 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
JP3884232B2 (ja) * 1999-03-29 2007-02-21 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化物質
JP2003531103A (ja) 1999-08-12 2003-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＪＵＮＮ−末端キナーゼ（ＪＮＫ）および他のタンパク質キナーゼの阻害剤
GB9921684D0 (en) 1999-09-15 1999-11-17 Zeneca Ltd Assays
AU780787B2 (en) * 1999-09-17 2005-04-14 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
WO2001035950A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
WO2001083465A2 (en) 2000-05-03 2001-11-08 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
EP1283830B1 (en) 2000-05-08 2008-06-18 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
AU8760001A (en) 2000-07-20 2002-02-05 Hoffmann La Roche Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US20040077690A1 (en) 2000-09-29 2004-04-22 Bing-Yan Zhu Quaternary amidino based inhibitors of factor xa
AU2002214546A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
ES2260336T3 (es) 2000-11-22 2006-11-01 Astellas Pharma Inc. Derivados de fenol sustituidos o sales de los mismos como inhibidores del factor de coagulacion x.
KR100545431B1 (ko) * 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
CA2432713C (en) * 2000-12-22 2009-10-27 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
ATE368643T1 (de) 2001-03-30 2007-08-15 Millennium Pharm Inc Faktor xa benzamidin inhibitoren
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
TWI325302B (en) 2001-08-13 2010-06-01 Du Pont Benzoxazinone compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2345993C2 (ru) 2001-09-21 2009-02-10 Бристол-Маерс Сквибб Компани ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
TWI283164B (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
JP2005526702A (ja) 2001-12-03 2005-09-08 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニストとの組み合わせにおける２型糖尿病治療のためのグルコキナーゼ活性化剤の使用
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
HUP0402309A3 (en) 2001-12-21 2008-09-29 Novo Nordisk As Amide derivatives as glucokinase activators and pharmaceutical compositions containing them
AU2003221140B9 (en) 2002-03-26 2009-07-30 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
PL373701A1 (en) 2002-04-26 2005-09-05 F.Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
AU2003235307A1 (en) 2002-05-16 2003-12-02 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004007472A1 (ja) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
ATE374768T1 (de) 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CN101712657A (zh) * 2003-02-26 2010-05-26 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
US20050165031A1 (en) * 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
RU2329261C2 (ru) 2003-12-29 2008-07-20 Баниу Фармасьютикал Ко., Лтд. Новое 2-гетероарил-замещенное производное бензимидазола
US8859581B2 (en) 2005-04-25 2014-10-14 Merck Patent Gmbh Azaheterocyclic compounds as kinase inhibitors

Also Published As

Publication number Publication date
EP1669068A1 (en) 2006-06-14
JP4441446B2 (ja) 2010-03-31
SI1568367T1 (sl) 2007-08-31
SI1661569T1 (sl) 2008-10-31
ES2312050T3 (es) 2009-02-16
JP2005320343A (ja) 2005-11-17
ATE406891T1 (de) 2008-09-15
PT1661569E (pt) 2008-08-18
DK1529530T5 (da) 2009-11-23
EP1568367B1 (en) 2007-04-18
BR0212008A (pt) 2004-09-28
EP1661567A1 (en) 2006-05-31
ES2309862T3 (es) 2008-12-16
DE60227120D1 (de) 2008-07-24
CY1105746T1 (el) 2010-12-22
EP1987831A1 (en) 2008-11-05
EP1420784A1 (en) 2004-05-26
EP1669069A1 (en) 2006-06-14
DE60210782D1 (de) 2006-05-24
ES2285341T7 (es) 2010-03-31
ES2312051T3 (es) 2009-02-16
EP1568367B3 (en) 2009-09-02
CY1108267T1 (el) 2014-02-12
HK1089958A1 (en) 2006-12-15
DK1568367T3 (da) 2007-07-30
ES2270263T7 (es) 2010-03-31
HK1076042A1 (en) 2006-01-06
UA83182C2 (en) 2008-06-25
DK1529530T3 (da) 2006-11-13
CN101584691A (zh) 2009-11-25
EP1529530A1 (en) 2005-05-11
ATE397927T1 (de) 2008-07-15
SI1529530T1 (sl) 2006-12-31
HK1090291A1 (en) 2006-12-22
US20090227592A1 (en) 2009-09-10
ATE397928T1 (de) 2008-07-15
CN101492416B (zh) 2012-02-22
SE0102764D0 (sv) 2001-08-17
EP1661567B1 (en) 2008-06-11
PT1529530E (pt) 2006-11-30
DE60213678T3 (de) 2010-02-25
HK1079692A1 (en) 2006-04-13
PT1661563E (pt) 2008-07-31
DE60213678T2 (de) 2007-08-09
EP1669069B1 (en) 2008-09-10
CN101492416A (zh) 2009-07-29
US7524957B2 (en) 2009-04-28
TW200911238A (en) 2009-03-16
DE60227119D1 (de) 2008-07-24
CN100577163C (zh) 2010-01-06
DE60228143D1 (de) 2008-09-18
HK1090839A1 (en) 2007-01-05
MY146279A (en) 2012-07-31
JP3987829B2 (ja) 2007-10-10
ES2306300T3 (es) 2008-11-01
WO2003015774A1 (en) 2003-02-27
EP1661568A1 (en) 2006-05-31
KR20040030125A (ko) 2004-04-08
DE60228770D1 (de) 2008-10-16
HK1089966A1 (en) 2006-12-15
CA2457410A1 (en) 2003-02-27
US7951830B2 (en) 2011-05-31
DE60219698T2 (de) 2007-12-27
EP1695705B1 (en) 2008-08-06
SI1661563T1 (sl) 2008-10-31
PT1568367E (pt) 2007-06-28
DE60219698T3 (de) 2010-02-25
ATE407672T1 (de) 2008-09-15
ATE334678T1 (de) 2006-08-15
HK1089960A1 (en) 2006-12-15
ATE323487T1 (de) 2006-05-15
ZA200401015B (en) 2005-05-06
DE60228897D1 (de) 2008-10-23
DK1661563T3 (da) 2008-08-25
IS7150A (is) 2004-02-13
EP1568367A1 (en) 2005-08-31
DK1661569T3 (da) 2008-09-15
DE60227122D1 (de) 2008-07-24
EP1529530B3 (en) 2009-09-02
ATE397929T1 (de) 2008-07-15
CY1107683T1 (el) 2013-04-18
CY1108254T1 (el) 2014-02-12
DE60210782T2 (de) 2007-05-10
DE60213678D1 (de) 2006-09-14
EP1420784B1 (en) 2006-04-19
MXPA04001500A (es) 2004-05-14
ATE397926T1 (de) 2008-07-15
NZ531193A (en) 2005-07-29
EP1661569A1 (en) 2006-05-31
RU2004104333A (ru) 2005-03-27
ES2307238T3 (es) 2008-11-16
IL160219A0 (en) 2004-07-25
EP1661568B1 (en) 2008-09-03
JP2005525291A (ja) 2005-08-25
HK1093429A1 (en) 2007-03-02
US7390908B2 (en) 2008-06-24
CN101704797A (zh) 2010-05-12
EP1661569B1 (en) 2008-06-11
ES2285341T3 (es) 2007-11-16
SI1669068T1 (sl) 2008-10-31
DE60219698D1 (de) 2007-05-31
ATE403427T1 (de) 2008-08-15
EP1674097B1 (en) 2008-06-11
EP1669068B1 (en) 2008-06-11
EP1661563B1 (en) 2008-05-28
US20050080106A1 (en) 2005-04-14
ES2307239T3 (es) 2008-11-16
EP1695705A1 (en) 2006-08-30
AU2002321462B2 (en) 2007-09-20
PL368970A1 (en) 2005-04-04
CN1568185A (zh) 2005-01-19
DK1669068T3 (da) 2008-09-22
HUP0401213A2 (hu) 2004-12-28
ATE396720T1 (de) 2008-06-15
RU2329043C2 (ru) 2008-07-20
EP1674097A1 (en) 2006-06-28
CY1108276T1 (el) 2014-02-12
HK1064598A1 (en) 2005-02-04
PT1669068E (pt) 2008-08-20
RU2329043C9 (ru) 2008-11-20
TWI333855B (en) 2010-12-01
ES2308609T3 (es) 2008-12-01
ES2270263T3 (es) 2007-04-01
AR037898A1 (es) 2004-12-22
CA2457410C (en) 2011-09-27
IL203923A (en) 2013-03-24
HK1090292A1 (en) 2006-12-22
DK1568367T5 (da) 2009-11-23
DE60227121D1 (de) 2008-07-24
KR100920439B1 (ko) 2009-10-08
ATE359781T1 (de) 2007-05-15
HUP0401213A3 (en) 2011-03-28
CO5560563A2 (es) 2005-09-30
EP1529530B1 (en) 2006-08-02
ES2307237T3 (es) 2008-11-16
DE60226914D1 (de) 2008-07-10
US20080207636A1 (en) 2008-08-28
EP1661563A1 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
NO20040686L (no) Forbindelser som pavirker glukokinase
NO20035766L (no) Aminonikotinatderivater som glukokinase (GLK) modulatorer
ATE402148T1 (de) Substituierte pyridinylamine
IS6971A (is) Ný efnasambönd
DE60211774D1 (de) Cryotechnische Schubeinheit
DE50206892D1 (de) Substituierte imidazotriazinone
NO20034949L (no) Sulfonamider
NO20014597D0 (no) Fremgangsmåte
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50202174D1 (de) Schliesszylinder
DE60231830D1 (de) Verriegelungsanordnung
DE60239393D1 (de) Verriegelungsanordnung
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
FI20011048A (fi) Tilajärjestely
DE50115802D1 (de) Dafür
DE60216967D1 (de) Substituierte cyclohexanderivate
DE60224192D1 (de) Antihaemorrhagische, betain-enthaltende zusammenseuzungen
SE0101958D0 (sv) New compounds
SE0100272D0 (sv) New compounds
SE0100629D0 (sv) New compounds
SE0101659D0 (sv) New compounds
SE0101660D0 (sv) New compounds
SE0104366D0 (sv) New compounds
SE0104342D0 (sv) New compounds
SE0103461D0 (sv) New compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application